Hemophilia Drug Development (HDD 2021) is a conference dedicated to the most pressing challenges in the broad spectrum of novel therapies in the treatment of hemophilia.
Hemophilia Drug Development (HDD 2021) covers topics such as:
- Mechanisms in next generation therapies to understand the biological impacts
- Optimizing patient-centric approaches to ensure patient engagement
- How to define endpoints in the era of new drugs
- The factors that influence patients to adopt novel therapies